<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414231</url>
  </required_header>
  <id_info>
    <org_study_id>AML 2002 #061</org_study_id>
    <nct_id>NCT01414231</nct_id>
  </id_info>
  <brief_title>Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML&lt;60a</brief_title>
  <acronym>OSHO#061</acronym>
  <official_title>Randomised Comparison of OSHO Induction vs. the German AML Intergroup Standard, Randomised Comparison of AraC/Mtx vs. Flu/AraC/Mtx in Pts Without CR After One Induction Cycle and Randomized Comparison of One vs. Two Consolidation Therapies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is part of the German AML Intergroup Trial, where the OSHO study arm is
      compared to the common German standard arm after randomization in a 9:1 ratio. The hypothesis
      involves primarily dosing and application of AraC for induction. It is expected that CR rates
      and as a consequence also LFS are higher in protocols using higher AraC compared to lower
      doses and that LFS might be superior in the study specific arm compared to the golden
      standard published several years ago. In the standard arm, AraC 100mg/m2/day is given as
      continuous infusion over 7 days. Daunorubicin is given as 60 mg/m2/day over a two hours
      infusion on days 3, 4 und 5. On day 22 a second induction course is applied. After reaching
      CR, three cycles of AraC 3 g/m2 over three hours bid are infused on day 1, 3 und 5. In
      contrast the OSHO arm consists of induction therapy with IDA 12 mg/m*2 over 20-30-min-iv on
      day 1 - 3 and AraC 2 x 1 g/m*2 bid over 3-h-iv on days 1+3+5+7.

      A previous phase II study of the OSHO has shown high CR in patients with relapsed AML using
      MitoFlag. In this study we asked the question if MitoFlag is superior to IdaAraC in newly
      diagnosed AML patients without CR after the first induction chemotherapy. Therefore patients
      are randomized to receive either MitoFlag or IdaAraC and the difference in CR rates
      evaluated.

      It is still unclear if two consolidation therapies are needed before allogeneic or autologous
      stem cell transplantation. This question is being addressed in the second part of the OSHO
      study, where patients are randomized to receive either one or two consolidation therapies.

      In this study all patients with AML and an age of 18-60 years except M3 are entered
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2002</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>after 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission</measure>
    <time_frame>average of 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 5 years average</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>at 5 years average</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Acute Myeloid Leukaemia</condition>
  <arm_group>
    <arm_group_label>Cytarabine low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the golden standard of AML treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytarabine intermediate dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the OSHO internal arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.</description>
    <arm_group_label>Cytarabine low dose</arm_group_label>
    <arm_group_label>Cytarabine intermediate dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult patients &lt; or = 60 years acute myelogenous leukemia (AML) AML t(8;21)(q22;q22), AML1
        (CBFa)/ETO, AML(inv(16)(p13q22)) und variants (CBFb/MYH11), AML 11q23, MLL-anomalies, AML
        with normal karyotyp myelodysplastic syndrome (MDS)RAEBT with 20-30% blasts.

        de novo AML secundary AML after MDS secundary AML after chemotherapy with alkylantien
        sekund√§re AML after chemotherapy with Epipodophyllotoxin informed consent

        Exclusion Criteria:

        AML M3 patients included in another clinical trial contraindications for high dose
        cytotoxic therapy such as renal insufficiency liver insufficiency cardiac insufficiency
        NYHA III + IV, acute myocardial infarction uncontroled infection like pneumonia with
        hypoxemia or septic schock pregnancy Karnofski-Index of 10 and less second maligancy
        severe, decompensated metabolism disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietger Niederwieser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dietger Niederwieser, Prof.</last_name>
    <phone>+49 172 3436202</phone>
    <email>dietger@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Leipzig, Hematology</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser</last_name>
      <phone>+4934197</phone>
      <phone_ext>13050</phone_ext>
      <email>dietger@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Dr. h. c. Dietger Niederwieser</name_title>
    <organization>University of Leipzig, Hematology</organization>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>acute myeloid leukaemia</keyword>
  <keyword>low vs intermediate dose AraC</keyword>
  <keyword>CR rate</keyword>
  <keyword>patients &lt;60 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

